BRPI0410634A - processo - Google Patents
processoInfo
- Publication number
- BRPI0410634A BRPI0410634A BRPI0410634-2A BRPI0410634A BRPI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A BR PI0410634 A BRPI0410634 A BR PI0410634A
- Authority
- BR
- Brazil
- Prior art keywords
- genes
- gene
- gene set
- nonresponders
- responders
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/65—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression using markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Plant Pathology (AREA)
- Pulmonology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
"PROCESSO". A invenção diz respeito a um conjunto de genes marcadores isolados que compreende pelo menos um gene identificado com expressão diferencial entre pacientes que são respondedores e não respondedores a um inibidor do receptor tirosina quinase erbB; o dito conjunto de genes compreendendo um ou mais genes selecionados pelo menos do grupo que consiste dos (51) genes listados anexos incluindo oligonucleotídeos específicos do gene derivado dos ditos genes; e usos de tais conjuntos em aplicações de diagnóstico.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0312451A GB0312451D0 (en) | 2003-05-30 | 2003-05-30 | Process |
GB0322636A GB0322636D0 (en) | 2003-09-26 | 2003-09-26 | Process |
GB0327132A GB0327132D0 (en) | 2003-11-21 | 2003-11-21 | Process |
PCT/GB2004/002316 WO2005049829A1 (en) | 2003-05-30 | 2004-06-01 | Process |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0410634A true BRPI0410634A (pt) | 2006-06-13 |
Family
ID=34623472
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0410634-2A BRPI0410634A (pt) | 2003-05-30 | 2004-06-01 | processo |
Country Status (12)
Country | Link |
---|---|
US (1) | US20060252056A1 (pt) |
EP (2) | EP2348110B1 (pt) |
JP (2) | JP4724657B2 (pt) |
KR (1) | KR101126560B1 (pt) |
AU (1) | AU2004291709C1 (pt) |
BR (1) | BRPI0410634A (pt) |
CA (1) | CA2527680A1 (pt) |
IL (1) | IL172029A (pt) |
MX (1) | MXPA05012939A (pt) |
NO (1) | NO20055459L (pt) |
NZ (1) | NZ543234A (pt) |
WO (1) | WO2005049829A1 (pt) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4724657B2 (ja) * | 2003-05-30 | 2011-07-13 | アストラゼネカ ユーケー リミテッド | プロセス |
US7700299B2 (en) | 2005-08-12 | 2010-04-20 | Hoffmann-La Roche Inc. | Method for predicting the response to a treatment |
JP2009505658A (ja) | 2005-08-24 | 2009-02-12 | ブリストル−マイヤーズ スクイブ カンパニー | 上皮増殖因子受容体モデュレーターに対する感受性を決定するためのバイオマーカーおよび方法 |
JP2007135581A (ja) * | 2005-10-20 | 2007-06-07 | Japan Science & Technology Agency | 自己免疫性血小板減少性紫斑病(itp)患者の血液細胞特異的遺伝子群 |
FI121236B (fi) * | 2006-01-18 | 2010-08-31 | Licentia Oy | Menetelmä asbestialtistukseen liittyvien keuhkosyöpien tunnistamiseksi |
US8138167B2 (en) | 2006-02-10 | 2012-03-20 | Oncotherapy Science, Inc. | Methods for treating lung cancers |
JPWO2007099852A1 (ja) * | 2006-02-23 | 2009-07-16 | 国立大学法人金沢大学 | 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット |
WO2007101122A2 (en) * | 2006-02-24 | 2007-09-07 | University Of Chicago | Methods and compositions involving slc17a1 |
US8288112B2 (en) | 2006-04-25 | 2012-10-16 | P&M Venge Ab | Protein, an antibody and measurement of the protein |
TW200817680A (en) | 2006-06-02 | 2008-04-16 | Glaxosmithkline Biolog Sa | Method |
EP2097754B2 (en) * | 2006-11-28 | 2018-01-24 | Daiichi Sankyo Europe GmbH | Activated her3 as a marker for predicting therapeutic efficacy |
CA2671399A1 (en) * | 2006-12-04 | 2008-06-12 | Abbott Laboratories | Companion diagnostic assays for cancer therapy |
EP2155877A2 (en) * | 2007-05-11 | 2010-02-24 | Santaris Pharma A/S | Rna antagonist compounds for the modulation of her3 |
JP2010535523A (ja) * | 2007-08-14 | 2010-11-25 | エフ.ホフマン−ラ ロシュ アーゲー | Egfrインヒビター処理のための予測マーカー |
WO2009021679A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treamtent |
CA2695473C (en) * | 2007-08-14 | 2013-10-01 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
BRPI0815414A2 (pt) * | 2007-08-14 | 2015-02-03 | Hoffmann La Roche | Marcador para o tratamento com inibidor de egfr |
KR20100037641A (ko) * | 2007-08-14 | 2010-04-09 | 에프. 호프만-라 로슈 아게 | Egfr 저해제 처리에 대한 예측성 마커 |
AU2008286407A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive markers for EGFR inhibitor treatment |
WO2009021675A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
MX2010001582A (es) * | 2007-08-14 | 2010-06-02 | Hoffmann La Roche | Marcador predictivo para tratamiento con el inhibidor del receptor del factor de crecimiento epidermico. |
ES2437122T3 (es) * | 2007-08-14 | 2014-01-09 | F. Hoffmann-La Roche Ag | Marcador predictivo en el tratamiento inhibidor del EGFR |
CA2695250A1 (en) * | 2007-08-14 | 2009-02-19 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
WO2010015535A1 (en) * | 2008-08-05 | 2010-02-11 | F. Hoffmann-La Roche Ag | Predictive marker for egfr inhibitor treatment |
GB0904957D0 (en) * | 2009-03-23 | 2009-05-06 | Univ Erasmus Medical Ct | Tumour gene profile |
EP2239578A1 (en) * | 2009-04-10 | 2010-10-13 | PamGene B.V. | Method for determining the survival prognosis of patients suffering from non-small cell lung cancer (NSCLC) |
US20120095030A1 (en) * | 2009-04-17 | 2012-04-19 | The Translational Genomics Research Institute | Methods and kits to predict therapeutic outcome of tyrosine kinase inhibitors |
GB0917457D0 (en) | 2009-10-06 | 2009-11-18 | Glaxosmithkline Biolog Sa | Method |
TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
WO2013056153A1 (en) * | 2011-10-13 | 2013-04-18 | Kung Charles | Activators of pyruvate kinase m2 and methods of treating disease |
TWI582239B (zh) * | 2013-03-11 | 2017-05-11 | 諾華公司 | 與wnt抑制劑相關之標記 |
EP3066474B1 (en) | 2013-11-05 | 2019-04-03 | Agency For Science, Technology And Research | Bladder carcinoma biomarkers |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9300059D0 (en) | 1992-01-20 | 1993-03-03 | Zeneca Ltd | Quinazoline derivatives |
US5837832A (en) | 1993-06-25 | 1998-11-17 | Affymetrix, Inc. | Arrays of nucleic acid probes on biological chips |
ATE446955T1 (de) | 1995-03-30 | 2009-11-15 | Pfizer Prod Inc | Chinazolinone derivate |
GB9508538D0 (en) | 1995-04-27 | 1995-06-14 | Zeneca Ltd | Quinazoline derivatives |
CA2224435C (en) | 1995-07-06 | 2008-08-05 | Novartis Ag | Pyrrolopyrimidines and processes for the preparation thereof |
US5760041A (en) | 1996-02-05 | 1998-06-02 | American Cyanamid Company | 4-aminoquinazoline EGFR Inhibitors |
GB9603095D0 (en) | 1996-02-14 | 1996-04-10 | Zeneca Ltd | Quinazoline derivatives |
HU228446B1 (en) | 1996-04-12 | 2013-03-28 | Warner Lambert Co | Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof |
US6002008A (en) | 1997-04-03 | 1999-12-14 | American Cyanamid Company | Substituted 3-cyano quinolines |
ES2201484T3 (es) | 1997-05-06 | 2004-03-16 | Wyeth Holdings Corporation | Utilizacion de compuestos de quinazolina para el tratamiento de la enfermedad de la poliquistosis renal. |
TW436485B (en) | 1997-08-01 | 2001-05-28 | American Cyanamid Co | Substituted quinazoline derivatives |
IL135622A0 (en) | 1997-11-06 | 2001-05-20 | American Cyanamid Co | Use of quinazoline derivatives as tyrosine kinase inhibitors for treating colonic polyps |
RS49779B (sr) | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
RS50081B (sr) | 1998-04-29 | 2009-01-22 | Osi Pharmaceuticals I.N.C., | N-(3-etinilfenilamino)-6,7-bis (2-metoksietoksi)-4- hinazolinamin mezilat, bezvodni i monohidrat |
DE69904358T2 (de) | 1998-11-19 | 2003-04-17 | Warner-Lambert Co., Morris Plains | N- 4-(3-chloro-4-fluoro-phenylamino)-7-(3-morfolin-4-yl-propoxy)-chinazolin-6-yl -akrylamid, ein irreversibler tyrosin-kinasen hemmer |
JP2000287680A (ja) * | 1999-04-09 | 2000-10-17 | Sentan Kagaku Gijutsu Incubation Center:Kk | 未成熟肝細胞を成熟肝細胞へ分化させる方法 |
EP1192151B1 (en) | 1999-07-09 | 2007-11-07 | Glaxo Group Limited | Anilinoquinazolines as protein tyrosine kinase inhibitors |
US7194269B2 (en) | 2000-10-30 | 2007-03-20 | Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of Industry | Method and wireless communication hub for data communications |
US7189507B2 (en) * | 2001-06-18 | 2007-03-13 | Pdl Biopharma, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
US7332590B2 (en) * | 2001-08-16 | 2008-02-19 | The United States Of America As Represented By The Department Of Health And Human Services | Molecular characteristics of non-small cell lung cancer |
WO2003040317A2 (en) * | 2001-11-02 | 2003-05-15 | Pfizer Products Inc. | Lung cancer therapeutics and diagnostics |
JP2006519620A (ja) * | 2003-03-04 | 2006-08-31 | アークチュラス バイオサイエンス,インコーポレイティド | 乳がんにおけるer状態の弁別特性 |
JP4724657B2 (ja) * | 2003-05-30 | 2011-07-13 | アストラゼネカ ユーケー リミテッド | プロセス |
-
2004
- 2004-06-01 JP JP2006516368A patent/JP4724657B2/ja not_active Expired - Fee Related
- 2004-06-01 AU AU2004291709A patent/AU2004291709C1/en not_active Ceased
- 2004-06-01 WO PCT/GB2004/002316 patent/WO2005049829A1/en active Application Filing
- 2004-06-01 CA CA002527680A patent/CA2527680A1/en not_active Abandoned
- 2004-06-01 EP EP10012191A patent/EP2348110B1/en not_active Expired - Lifetime
- 2004-06-01 MX MXPA05012939A patent/MXPA05012939A/es active IP Right Grant
- 2004-06-01 EP EP04735607A patent/EP1633870B1/en not_active Expired - Lifetime
- 2004-06-01 KR KR1020057020407A patent/KR101126560B1/ko not_active IP Right Cessation
- 2004-06-01 BR BRPI0410634-2A patent/BRPI0410634A/pt not_active IP Right Cessation
- 2004-06-01 NZ NZ543234A patent/NZ543234A/en not_active IP Right Cessation
-
2005
- 2005-11-17 IL IL172029A patent/IL172029A/en not_active IP Right Cessation
- 2005-11-18 NO NO20055459A patent/NO20055459L/no not_active Application Discontinuation
- 2005-11-30 US US11/290,173 patent/US20060252056A1/en not_active Abandoned
-
2011
- 2011-02-16 JP JP2011030571A patent/JP5217010B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
JP2011167188A (ja) | 2011-09-01 |
EP1633870B1 (en) | 2013-03-27 |
NO20055459L (no) | 2006-02-27 |
MXPA05012939A (es) | 2006-05-17 |
AU2004291709A1 (en) | 2005-06-02 |
NZ543234A (en) | 2009-04-30 |
EP1633870A1 (en) | 2006-03-15 |
AU2004291709B2 (en) | 2009-09-10 |
KR20060002012A (ko) | 2006-01-06 |
KR101126560B1 (ko) | 2012-04-05 |
IL172029A (en) | 2011-06-30 |
JP2006526420A (ja) | 2006-11-24 |
WO2005049829A1 (en) | 2005-06-02 |
JP5217010B2 (ja) | 2013-06-19 |
AU2004291709C1 (en) | 2010-03-11 |
EP2348110B1 (en) | 2013-03-27 |
EP2348110A1 (en) | 2011-07-27 |
US20060252056A1 (en) | 2006-11-09 |
JP4724657B2 (ja) | 2011-07-13 |
NO20055459D0 (no) | 2005-11-18 |
CA2527680A1 (en) | 2005-06-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0410634A (pt) | processo | |
DK0759927T3 (da) | Pteridinnucleotidanaloger som fluorescerende DNA prober | |
Mäser et al. | Drug transport and drug resistance in African trypanosomes | |
Winkelman et al. | Open complex scrunching before nucleotide addition accounts for the unusual transcription start site of E. coli ribosomal RNA promoters | |
DE69333073D1 (de) | Verwendungen von fluoreszierenden n-nukleosiden und dessen analogen | |
WO2004035765A3 (en) | Double-stranded rna structures and constructs, and methods for generating and using the same | |
WO2004011624A3 (en) | Double stranded rna structures and constructs, and methods for generating and using the same | |
BR9910174A (pt) | Processo para se obter um gene recombinante otimizado de resistência à praga, biblioteca, e, processo para se obter um organismo que seja patogênico a uma praga de vegetal | |
ATE416183T1 (de) | Oligonukleotide mit alternierenden segmenten und deren verwendungen | |
BRPI0519959A2 (pt) | copolìmero de (met)acrilato aniÈnico parcialmente neutralizado | |
BR9812650A (pt) | ácidos nucléicos hibridizando marcação múltipla, preparação dos mesmos, composições, formulação, kits e aplicações | |
DE60216798D1 (de) | Azyklische linker enthaltende oligonukleotide und deren verwendungen | |
NO973838D0 (no) | DNA-molekyler, deres fremstilling samt anvendelse ved genterapi | |
YU49101A (sh) | Karboksiaril supstituisani difenil karbamidi kao inhibitori raf kinaze | |
DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
BR9909110A (pt) | Usos de esmilagenina e anzurogenina d, compoisção farmacêutica tendo propriedades intensificadoras da função cognitiva, processo para intensificar a função cognitiva, e, composição para uso do mesmo | |
BRPI0414532A (pt) | composto, processo para preparar o mesmo, composição farmacêutica, uso de um composto, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
BR9811006A (pt) | Sequência de dna, cassete de expressão, uso do mesmo, processo para transformar uma planta, planta com um elevado teor em vitamina e, processo para gerar plantas com um elevado teor em vitamina e e para gerar plantas com elevada resistência a inibidores de hppd, sistema de teste, subtância herbicamente ativa, uso de uma planta, e, planta com elevada resistência a inibidores de hppd | |
Nardella et al. | DNA methylation bisubstrate inhibitors are fast-acting drugs active against artemisinin-resistant Plasmodium falciparum parasites | |
BR0317284A (pt) | Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno | |
Peuker et al. | α-Cardiac-like myosin heavy chain as an intermediate between MHCIIa and MHCIβ in transforming rabbit muscle | |
WO2004078941A3 (en) | Modulation of gene expression using dna-rna hybrids | |
DE69815370D1 (de) | Fluoreszend-konjugaten von nukleosiden und von nukleotiden, ihrer verfahren zur herstellung und ihrer verwendungen | |
BR0303092A (pt) | Portfólio para prognóstico de câncer de mama | |
Lavogina et al. | Targeting Plasmodium falciparum protein kinases with adenosine analogue–oligoarginine conjugates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2206 DE 16/04/2013. |